Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
"We are highly encouraged by the progress with Janssen in the successful application of our technology platform for the discovery and development of gut-restricted IL-23 receptor antagonist peptides as oral targeted therapy for IBD," commented
According to the terms of the agreement between Protagonist and Janssen, Protagonist is eligible to receive potential payments over the life of the collaboration. The payments are in the form of research, development, regulatory and sales milestones linked to development of PTG-200 and related compounds. Protagonist also has an option to co-detail PTG-200 and related compounds in the U.S. market.
About PTG-200 (JNJ-67864238)
PTG-200 is an oral peptide interleukin-23 receptor (IL-23R) antagonist being co-developed with Janssen for the treatment of inflammatory bowel disease and is initially in development for the treatment of patients with Crohn's disease. PTG-200 is designed to offer choices to patients in addition to injectable antibody therapeutics that target the IL-23 pathway, including the potential for improved safety and tolerability and better compliance compared to therapeutics administered by injection. Results from a Phase 1 randomized, double blind, placebo-controlled, single- and multiple-dose escalation study in healthy volunteers demonstrated that PTG-200 was well tolerated, with pharmacokinetic measures consistent with its design as a compound restricted to the gastrointestinal system. Protagonist and Janssen are jointly conducting a global, randomized, double blind, Phase 2 proof-of-concept study of PTG-200 in 90 patients with moderate to severe Crohn's disease. Additional information on the PTG-200 Crohn's disease study is available at https://clinicaltrials.gov/ct2/show/NCT04102111.
About
Protagonist is headquartered in
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions or current expectations concerning, among other things, the development and potential of PTG-200 as a possible treatment for inflammatory bowel disease, the timing and results of clinical trials for PTG-200, the results of our collaboration agreement with Janssen and the timing of any payments from the collaboration agreement with Janssen. In some cases, you can identify these statements by forward-looking words such as "plan," "will," "expect," "potential," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreement with Janssen, our ability to use and expand our programs to build a pipeline of product candidates, and our ability to obtain and maintain regulatory approval of our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the
View original content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-achieves-milestone-in-janssen-biotech-inc-collaboration-300982248.html
SOURCE
Solebury Trout, Rich Allan (media), Tel: +1 646-378-2958, Email: rallan@soleburytrout.com; Brian Korb (investors), Tel: +1 646-378-2923, Email: bkorb@soleburytrout.com